Form 4: Zymeworks EVP Sells Shares for Tax Obligations

Zymeworks' EVP & Chief Medical Officer, Jeffrey T L Smith, sold 10,538 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

Summary

• Jeffrey T L Smith, Executive Vice President and Chief Medical Officer of Zymeworks Inc. (ZYME), reported transactions on January 5, 2026.
• Acquired 20,000 shares of Zymeworks common stock upon the vesting of one-third of his restricted stock units (RSUs) that were granted on January 5, 2024.
• Disposed of 10,538 shares of common stock at a weighted average price of $25.0969 per share.
• The sale was a mandatory 'sell to cover' transaction, specifically to satisfy tax withholding obligations and other applicable fees related to the RSU vesting, and was not a discretionary sale.
• Following these transactions, Smith beneficially owns 18,352 shares of common stock and 20,000 restricted stock units.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax obligations related to RSU vesting, indicating neither a strong positive nor negative discretionary action by the executive. It is a neutral event from an investment sentiment perspective.

Positives

• The vesting of restricted stock units indicates continued executive compensation and retention of a key management member.
• The sale was non-discretionary, solely for tax purposes, suggesting it does not reflect a change in the executive's confidence in the company.

Negatives

• A reduction in the direct beneficial ownership of common stock by a key executive, even if for tax purposes, represents a decrease in their direct equity stake.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sale of shares to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs was pursuant to mandatory 'sell to cover' provisions and does not represent a discretionary sale by the Reporting Person.

Industry Context

This insider transaction report is specific to an individual executive's compensation and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The transaction involves a minor, non-discretionary reduction in a key executive's direct common stock ownership, which is a standard part of executive compensation plans.
• Employees: Reflects the standard compensation structure for executives, including equity awards.

Next Steps

• Future annual vesting installments of the remaining Restricted Stock Units granted on January 5, 2024, will occur.

Key Dates

Recommendation

This Form 4 reports a routine 'sell to cover' transaction by an executive to satisfy tax obligations upon RSU vesting. It does not reflect a discretionary sale or a change in the executive's confidence in the company. Therefore, it provides no new fundamental information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

Zymeworks, ZYME, Form 4, Insider Transaction, Restricted Stock Units, RSU, Executive Compensation, Stock Sale, Tax Withholding